TSD statistical model - with multiple sites [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2021-10-12 11:27 (11 d 17:31 ago) – Posting: # 22625
Views: 140

Hi d_stat,

» » […] Originally we wanted to go with a variant of ‘Method C’ cause it’s slightly more powerful (esp. when you expect to stop in the IA with BE) and it is preferred by the FDA.
» Thus, we are sticking to Potvin.

I wouldn’t. It might be that the site-model mentioned above is not stable. When I tried to add ‘sites’ to Potvin’s ‘Example 2’ (subjects 1–4: 1, 5–8: 2, 9–12: 3), Phoenix/WinNonlin showed me the finger.

» In order to do the validations for multiple-site nature of the study we are thinking of amending the code in the Power2Stage, since it's not part of package yet. Am I wrong to assume the amendment will be connected to decreasing of df for the error term with the number planned sites, …

That’s correct.

» … or is there any other part that I am missing?

You would also have to modify the degrees of freedom in the function to re-estimate the sample size (sampsiz2.R).

» Of course, the alternative is always to encourage (pray to) the holy trinity to update the package ;-)

Sorry. I'm afraid your prayers will not be answered.

Maurer’s method as implemented in Power2Stage allows already to provide the degrees of freedom and the standard error of the means of a more complex model than the conventional 2×2×2 crossover.Hence, why the efforts?

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,753 posts in 4,548 threads, 1,544 registered users;
online 19 (0 registered, 19 guests [including 3 identified bots]).
Forum time: Sunday 04:58 CEST (Europe/Vienna)

They were “so intent of making everything numerical”
that they frequently missed seeing
what was there to be seen.    Barbara McClintock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz